The potential of using itaconate as treatment for inflammation-related heart diseases

Intracellular metabolites can cause critical changes in biological functions. Itaconate is perhaps the most fascinating substance in macrophages. Lipopolysaccharide can activate aconitate decarboxylase 1 and induces the generation of itaconate from the tricarboxylic acid cycle by decarboxylation of...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui-Chen Ku, Ta-Chung Shen, Ching-Feng Cheng
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Tzu Chi Medical Journal
Subjects:
Online Access:http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=2;spage=113;epage=118;aulast=Ku
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850216150250553344
author Hui-Chen Ku
Ta-Chung Shen
Ching-Feng Cheng
author_facet Hui-Chen Ku
Ta-Chung Shen
Ching-Feng Cheng
author_sort Hui-Chen Ku
collection DOAJ
description Intracellular metabolites can cause critical changes in biological functions. Itaconate is perhaps the most fascinating substance in macrophages. Lipopolysaccharide can activate aconitate decarboxylase 1 and induces the generation of itaconate from the tricarboxylic acid cycle by decarboxylation of cis-aconitate. It has been reported that itaconate has beneficial effects on inflammation and oxidation. The mechanisms involved in these effects include the suppression of succinate dehydrogenase, the activation of nuclear factor E2-related factor 2 by alkylation of Kelch-like ECH-associated protein 1, suppression of aerobic glycolysis through regulation of glyceraldehyde-3-phosphate dehydrogenase and fructose-bisphosphate aldolase A, and suppression of IκBζ translation through activating transcription factor 3 activation. All of these findings elucidated the possible therapeutic implications of itaconate in inflammation-related diseases. In this review, we highlight that itaconate is a crucial molecule of the immunomodulatory response in macrophages and can regulate between immune response and cardiovascular metabolism. Furthermore, these discoveries suggest that itaconate is a very novel therapeutic molecule for the treatment of inflammation-related heart diseases.
format Article
id doaj-art-41b6f6e1cbc2454f9ab29ca06a7206d0
institution OA Journals
issn 1016-3190
2223-8956
language English
publishDate 2022-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Tzu Chi Medical Journal
spelling doaj-art-41b6f6e1cbc2454f9ab29ca06a7206d02025-08-20T02:08:24ZengWolters Kluwer Medknow PublicationsTzu Chi Medical Journal1016-31902223-89562022-01-0134211311810.4103/tcmj.tcmj_83_21The potential of using itaconate as treatment for inflammation-related heart diseasesHui-Chen KuTa-Chung ShenChing-Feng ChengIntracellular metabolites can cause critical changes in biological functions. Itaconate is perhaps the most fascinating substance in macrophages. Lipopolysaccharide can activate aconitate decarboxylase 1 and induces the generation of itaconate from the tricarboxylic acid cycle by decarboxylation of cis-aconitate. It has been reported that itaconate has beneficial effects on inflammation and oxidation. The mechanisms involved in these effects include the suppression of succinate dehydrogenase, the activation of nuclear factor E2-related factor 2 by alkylation of Kelch-like ECH-associated protein 1, suppression of aerobic glycolysis through regulation of glyceraldehyde-3-phosphate dehydrogenase and fructose-bisphosphate aldolase A, and suppression of IκBζ translation through activating transcription factor 3 activation. All of these findings elucidated the possible therapeutic implications of itaconate in inflammation-related diseases. In this review, we highlight that itaconate is a crucial molecule of the immunomodulatory response in macrophages and can regulate between immune response and cardiovascular metabolism. Furthermore, these discoveries suggest that itaconate is a very novel therapeutic molecule for the treatment of inflammation-related heart diseases.http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=2;spage=113;epage=118;aulast=Kuactivating transcription factor 3inflammationitaconatenuclear factor erythroid 2-related factor 2succinate dehydrogenase
spellingShingle Hui-Chen Ku
Ta-Chung Shen
Ching-Feng Cheng
The potential of using itaconate as treatment for inflammation-related heart diseases
Tzu Chi Medical Journal
activating transcription factor 3
inflammation
itaconate
nuclear factor erythroid 2-related factor 2
succinate dehydrogenase
title The potential of using itaconate as treatment for inflammation-related heart diseases
title_full The potential of using itaconate as treatment for inflammation-related heart diseases
title_fullStr The potential of using itaconate as treatment for inflammation-related heart diseases
title_full_unstemmed The potential of using itaconate as treatment for inflammation-related heart diseases
title_short The potential of using itaconate as treatment for inflammation-related heart diseases
title_sort potential of using itaconate as treatment for inflammation related heart diseases
topic activating transcription factor 3
inflammation
itaconate
nuclear factor erythroid 2-related factor 2
succinate dehydrogenase
url http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2022;volume=34;issue=2;spage=113;epage=118;aulast=Ku
work_keys_str_mv AT huichenku thepotentialofusingitaconateastreatmentforinflammationrelatedheartdiseases
AT tachungshen thepotentialofusingitaconateastreatmentforinflammationrelatedheartdiseases
AT chingfengcheng thepotentialofusingitaconateastreatmentforinflammationrelatedheartdiseases
AT huichenku potentialofusingitaconateastreatmentforinflammationrelatedheartdiseases
AT tachungshen potentialofusingitaconateastreatmentforinflammationrelatedheartdiseases
AT chingfengcheng potentialofusingitaconateastreatmentforinflammationrelatedheartdiseases